Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00

Beam Therapeutics (NASDAQ:BEAM) had its price objective upped by research analysts at Royal Bank Of Canada from $22.00 to $26.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective points to a potential downside of 18.94% from the company’s previous close.

A number of other brokerages have also recently issued reports on BEAM. Wedbush lifted their price objective on Beam Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. UBS Group initiated coverage on shares of Beam Therapeutics in a research note on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price target on the stock. Sanford C. Bernstein lifted their price target on shares of Beam Therapeutics from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Canaccord Genuity Group started coverage on Beam Therapeutics in a report on Friday. They issued a “buy” rating and a $74.00 price target for the company. Finally, Benchmark reaffirmed a “speculative buy” rating on shares of Beam Therapeutics in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.19.

Beam Therapeutics Stock Down 0.7%

BEAM traded down $0.22 during trading hours on Wednesday, hitting $32.08. The stock had a trading volume of 488,176 shares, compared to its average volume of 1,846,002. The company’s fifty day simple moving average is $28.74 and its 200 day simple moving average is $24.99. Beam Therapeutics has a 1 year low of $13.52 and a 1 year high of $36.44. The stock has a market cap of $3.25 billion, a PE ratio of -7.18 and a beta of 2.12.

Beam Therapeutics (NASDAQ:BEAM) last posted its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $3.46. Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. The business had revenue of $114.11 million for the quarter, compared to analyst estimates of $13.22 million. During the same quarter in the prior year, the firm posted ($1.09) EPS. Beam Therapeutics’s revenue was up 280.3% on a year-over-year basis. As a group, equities analysts expect that Beam Therapeutics will post -4.57 EPS for the current year.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 1,371 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $34.00, for a total value of $46,614.00. Following the completion of the transaction, the insider owned 95,667 shares of the company’s stock, valued at $3,252,678. This trade represents a 1.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 3.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Beam Therapeutics

Several large investors have recently bought and sold shares of the stock. ARK Investment Management LLC lifted its stake in Beam Therapeutics by 24.8% in the third quarter. ARK Investment Management LLC now owns 11,038,834 shares of the company’s stock worth $267,913,000 after acquiring an additional 2,190,993 shares during the last quarter. Contrarius Group Holdings Ltd acquired a new stake in shares of Beam Therapeutics in the 3rd quarter valued at $37,212,000. MWG Caph Ltd purchased a new stake in shares of Beam Therapeutics during the 4th quarter worth $35,119,000. State Street Corp grew its stake in shares of Beam Therapeutics by 30.4% during the fourth quarter. State Street Corp now owns 5,228,529 shares of the company’s stock worth $144,935,000 after purchasing an additional 1,219,871 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Beam Therapeutics by 237.5% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,665,385 shares of the company’s stock worth $40,419,000 after purchasing an additional 1,171,977 shares in the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Beam Therapeutics News Roundup

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Q4 results materially beat expectations — company reported $2.33 EPS and $114.1M revenue (well above estimates), driving investor re-rating. Press Release
• Positive Sentiment: Strategic financing: $500M facility with Sixth Street (non-dilutive, seven-year term; $100M drawn at close, up to $400M available) to support potential launch of ristoglogene autogetemcel (risto‑cel) in sickle cell disease — bolsters liquidity and lowers near-term dilution risk. Financing Release
• Positive Sentiment: Wedbush raised its price target to $65 and kept an “outperform” rating — signals stronger sell‑side conviction and adds impetus for further upside. Benzinga
• Positive Sentiment: Pipeline progress — announced a liver-targeted program for PKU with a platform approach and an IND for BEAM‑304 expected in 2026, supporting longer‑term clinical value creation. GEN Eng News
• Neutral Sentiment: Corporate communications — investor webcast and earnings call materials are available (useful for details on margin drivers, product timelines and use of financing). Earnings Highlights
• Neutral Sentiment: Analyst/press coverage and presentation decks published (good sources to review management commentary and modeling assumptions). Presentation
• Negative Sentiment: Structural profitability concerns remain: company still shows negative net margin and negative ROE on trailing metrics, and some sell‑side forecasts expect negative full‑year EPS (~-4.57), so sustainability of the quarter’s profit and long‑term cash flow profile are open questions for investors. Analyst Data

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.